YLYun Hee Lee

Yun Hee Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yun Hee Lee has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Bae Kwon Jeong

    Institute of Health Science, Gyeongsang National University, Jinju, Korea

    6 shared publications
  • Hoon Sik Choi

    Department of Radiation Oncology Gyeongsang National University School of Medicine and Gyeongsang National University Changwon Hospital Changwon Republic of Korea

    5 shared publications
  • Jin Ho Song

    Department of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University, Seoul, Korea

    5 shared publications
  • Hojin Jeong

    Department of Radiation Oncology, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, Republic of Korea

    4 shared publications
  • In Bong Ha

    Department of Radiation Oncology, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea

    4 shared publications
  • Ki Mun Kang

    Department of Radiation Oncology Gyeongsang National University School of Medicine and Gyeongsang National University Changwon Hospital Changwon Republic of Korea

    4 shared publications

Latest Publications

  • Effectiveness of stereotactic body radiotherapy for portal vein tumor thrombosis in patients with hepatocellular carcinoma and underlying chronic liver disease

    by Hoon Sik Choi, Ki Mun Kang, Bae Kwon Jeong, Hojin Jeong, Yun Hee Lee, In Bong Ha, Jin Ho Song

    Aim: Stereotactic‐body radiotherapy (SBRT) is a treatment option for portal vein tumor thrombosis (PVTT) in patients with hepatocellular carcinoma (HCC). Here, we report on our experience of treating PVTT using SBRT in patients with concomitant underlying chronic liver disease.Methods: This study included 24 patients. The initial prescription dose was 45 Gy in three fractions in 17 (70.8%) patients, but it was modified in the remaining seven (29.2%) patients, with the dose ranging from 39 to 42 Gy in 3‐4 fractions. After SBRT, transarterial chemoembolization (TACE) was performed in 16 (66.7%) patients.Results: Of the 24 patients, 2 (8.3%) showed complete response, while 11 (45.8%) showed partial response. After a median follow‐up of 8.4 months (range: 2.6‐56.5 months), the 1‐year overall survival (OS) and the median survival were 67.5% and 20.8 months, respectively. Both combined SBRT and TACE and grade ≥3 hepatic toxicity affected the 1‐year OS (SBRT alone vs SBRT + TACE: 14.6% vs 71.4%, P < .001; presence of hepatic toxicity vs absence: 0% vs 81.1%, P = .002).Conclusions: Overall, SBRT, especially in combination with TACE, is an effective treatment for patients with HCC and PVTT. An optimal dose schedule must be followed to reduce hepatic toxicity while maintaining tumor response.


  • Stereotactic-body radiotherapy for portal vein tumor thrombosis in hepatocellular carcinoma patients.

    by Bae Kwon Jeong, Hoon Sik Choi, Ki Mun Kang, Hojin Jeong, Yun Hee Lee, In Bong Ha, Jin Ho Song

    442 Background: Portal vein tumor thrombosis (PVTT) is commonly accompanied by hepatocellular carcinoma (HCC) patients, and in these cases the treatment options became limited and treatment outcome was poor. Stereotactic body radiotherapy (SBRT) is one of the possible treatment options, which can deliver higher doses with highly conformal target have conducted for treatment of PVTT. However, only few studies about the SBRT have reported, even treatment schedules were not consistent. In this study, we report our institutional experience of treating PVTT in HCC patients using SBRT. Methods: 24 HCC patients with PVTT were treated with SBRT at our institution. All patients had unresectable HCC with PVTT, baseline liver function of Child-Pugh class A or B. SBRT was performed by Cyberknife based on 4D-simulation and 4D-planning. The prescription dose was 45 Gy in 3 fractions in 17 (70.8%) patients, and was modified to 39 to 42 Gy in 3 to 4 fractions in 7 (29.2%) patients whose target was large or adjacent to the bowel. After SBRT, transarterial chemoembolization (TACE) was performed in 16 (66.7%) patients within 3 months. Results: There were 2 (8.3%) patients of PVTT showed complete response, and 11 (45.8%) patients showed partial response. Stable disease was found in 7 (29.2%) patients, and progression in 4 (16.7%) patients. The response rate was lower in patients with tumor thrombus at main portal vein than those at branch of portal vein (main, 30% vs. branch, 71.4%, p = 0.052). The 1- and 2-year overall survival (OS) was 67.5%, 48.2%, respectively, with median survival of 20.8 months. The combination SBRT followed by TACE, and presence of grade 3 hepatic toxicities impacted on survival. The 1-year OS was 71.4% in patients whom TACE was combined after SBRT, which was higher than that of 14.6% who were treated with SBRT alone (p < 0.001). The 1-year OS was 81.1% in patients who did not occur grade 3 hepatic toxicity, while 0% in patients who had grade 3 hepatic toxicity (p = 0.002). Conclusions: SBRT is a relatively effective treatment option for HCC patients of PVTT. Especially combined with TACE. Finding an optimal dose schedule which can reduce hepatic toxicity, while keeping the response seems important to increase the survival.


  • Open Access

    Who Really Benefits from 3D-Based Planning of Brachytherapy for Cervical Cancer?

    by In Bong Ha, Bae Kwon Jeong, Ki Mun Kang, Hojin Jeong, Yun Hee Lee, Hoon Sik Choi, Jong Hak Lee, Won Jun Choi, Jeong Kyu Shin, Jin Ho Song

    Ha IB, et al. J Korean Med Sci. 2018 Apr;33(18):e135. https://doi.org/10.3346/jkms.2018.33.e135


  • Open Access

    Analysis of Motion-dependent Clinical Outcome of Tumor Tracking Stereotactic Body Radiotherapy for Prostate Cancer

    by Hoon Sik Choi, Ki Mun Kang, Bae Kwon Jeong, Jin Ho Song, Yun Hee Lee, In Bong Ha, Sung Chul Kam, Jeong Seok Hwa, Jae Seog Hyun, Jungmo Do, et al.

    Choi HS, et al. J Korean Med Sci. 2018 Mar;33(14):e107. https://doi.org/10.3346/jkms.2018.33.e107


  • Open Access

    Defining the Optimal Time of Adaptive Replanning in Prostate Cancer Patients with Weight Change during Volumetric Arc Radiotherapy: A Dosimetric and Mathematical Analysis Using the Gamma Index

    by Hoon Sik Choi, Guang Sub Jo, Jong Pyo Chae, Sang Bong Lee, Chul Hang Kim, Bae Kwon Jeong, Hojin Jeong, Yun Hee Lee, In Bong Ha, Ki Mun Kang, et al.

    We evaluated the changes in the dose distribution of radiation during volumetric arc radiotherapy (VMAT), to determine the right time for adaptive replanning in prostate cancer patients with progressive weight (WT) changes. Five prostate cancer patients treated with VMAT were selected for dosimetric analysis. On the original computed tomography images, nine artificial body contours were created to reflect progressive WT changes. Combined with three different photon energies (6, 10, and 15-MV), 27 comparable virtual VMAT plans were created per patient. The dosimetric analysis included evaluation of target coverage (D95%,Dmax), conformity index, homogeneity index, and organs at risk doses. The dose differences among the plans were determined using the gamma index analysis and were compared with the dosimetric analysis. Mean D95% became lower than 98% when body contour expanded by 2.0 cm or more and Dmax became higher than 107% when body contour contracted by 1.5 cm or more in 10-MV plans. This cut-off values correlated well with gamma index analysis results. Adaptive replanning should, therefore, be considered if the depth of body contour becomes 1.5 cm smaller (WT loss) or 2.0 cm larger (WT gain) in patients treated by VMAT with 10-MV photons.


  • Neutrophil‐lymphocyte ratio and a dosimetric factor for predicting symptomatic radiation pneumonitis in non‐small‐cell lung cancer patients treated with concurrent chemoradiotherapy

    by Yun Hee Lee, Hoon‐Sik Choi, Hojin Jeong, Ki Mun Kang, Jin Ho Song, Won Sup Lee, Gyeong‐Won Lee, Haa‐Na Song, Hoon‐Gu Kim, Myoung Hee Kang, et al.

    Objectives: To identify the factors that predict the progression of radiological radiation pneumonitis (RP) to symptomatic RP, and to evaluate the usefulness of the neutrophil‐lymphocyte ratio (NLR) as a marker of RP severity and prognosis in stage III non‐small cell lung cancer (NSCLC) patients treated with definitive concurrent chemoradiotherapy (CCRT).Materials and Methods: We retrospectively reviewed 61 patients treated between January 2010 and December 2015. Patients' demographic characteristics, clinical data, laboratory findings and treatment parameters were analyzed to determine the predictive factors associated with progression from radiological RP to symptomatic RP.Results: Forty‐seven patients (77%) exhibited radiological RP at a median of 78 days after radiation therapy (RT) completion, and 15 (32%) of these patients developed symptomatic RP. The interval between RT completion and radiological RP presentation was shorter in patients who progressed to symptomatic RP (P = .001); progression was highly probable if this latency period was ≤2 months (P = .002). Stage and RT technique correlated with symptomatic RP development (P = .046 and P = .046, respectively). Among dosimetric factors, a V20 (defined as the lung volume receiving ≥20 Gy) of >30% was the most significant predictor of symptomatic RP (P = .001). The NLR and C‐reactive protein level at radiological RP were higher in patients who developed symptomatic RP (P = .067 and P = .012, respectively). On multivariate analysis, a V20 >30% and an NLR at radiological RP >6 were associated with symptomatic RP development.Conclusion: The NLR at radiological RP is a useful biomarker for predicting symptomatic RP development after CCRT in stage III NSCLC patients.


  • Using primary tumor volumetry to predict treatment outcome for patients with oropharyngeal cancer who were treated with definitive chemoradiotherapy

    by Yun Hee Lee, Jin Ho Song, Hoon‐Sik Choi, Hojin Jeong, Ki Mun Kang, Jung Hun Kang, Seung Hoon Woo, Jung Je Park, Jin Pyeong Kim, Bae Kwon Jeong

    Aim: This study aimed to determine predictive values for volumetric measures in patients with oropharyngeal cancer who received definitive chemoradiotherapy (CCRT).Methods: Contrast‐enhanced computed tomography (CT) scans were obtained before radiotherapy (RT) (I), after delivering a median RT of 50.6 Gy (R) and three months after RT (F). Primary site gross tumor volumes (GTV) were assessed using these scans (GTVI, GTVR and GTVF). The percentage volume change between GTVI and GTVR (GTV change) was calculated. Volumetric analyses of primary site local control (LC) and progression‐free survival (PFS) were performed.Results: In total, 35 patients were evaluated, with a median 31 months of follow‐up. The 2‐year LC rates (LCRs) were 95.0% for patients with GTVI I ≥23 cc (P = 0.001); the 2‐year PFS rates were 85.9% and 21.9% (P = 0.002), respectively. Using GTVR classifications vs 33.3%, P < 0.001) and 2‐year PFS (86.5% vs 0%, P < 0.001). There was no local progression in patients with GTV change ≥75%, and GTV change predicted poor PFS (P = 0.026). On multivariate analysis, GTVR ≥11 cc was a significant predictor of poor LCR (hazard ratio [HR] = 26, P = 0.009) and PFS (HR = 8.33, P = 0.046).Conclusion: For patients with oropharyngeal cancer treated with definitive CCRT, GTVI, GTVR and GTV changes predicted LC and PFS; GTVR was the most significant predictor of LC and PFS. RT intensification should be considered for patients with larger remaining tumors after CCRT.